OJPsych  Vol.5 No.3 , July 2015
Differences in Baseline Characteristics of Patients Treated with Olanzapine or Other Antipsychotics in Japanese Patients with Acute Schizophrenia: A 1-Year Observational Study under Routine Clinical Practice in Japan
Abstract: Objective: Baseline characteristics of acute schizophrenia patients were analyzed to identify differences in the baseline characteristics of patients treated with olanzapine monotherapy compared with those treated with other antipsychotic monotherapies. Methods: This prospective, naturalistic observational study was designed to evaluate discontinuation rates of olanzapine and non-olanzapine antipsychotic monotherapy in Japanese adult patients with acute schizophrenia. Results: A total of 1089 patients were assessed: 578 patients were treated with olanzapine, 487 with non-olanzapine atypical antipsychotics, and 24 with typical antipsychotics. The mean Clinical Global Impression-Severity (CGI-S) Schizophrenia, Brief Psychiatric Rating Scale (BPRS) total, and BPRS positive scores were higher in patients treated with olanzapine compared with most of the non-olanzapine treated patients. The majority of patients with a CGI-S Schizophrenia score of 7 (29/41 patients) as well as patients with a BPRS total score of 90 or higher (14/18 patients) were treated with olanzapine. On the other hand, physicians tended to prescribe antipsychotics other than olanzapine for patients with heavier body weight or diabetes mellitus. Conclusion: The present study demonstrated that olanzapine was more likely to be prescribed to patients with more severe schizophrenia symptoms. However, further studies are warranted to reach a definite conclusion.
Cite this paper: Takahashi, M. , Fujikoshi, S. , Funai, J. , Alev, L. and Iyo, M. (2015) Differences in Baseline Characteristics of Patients Treated with Olanzapine or Other Antipsychotics in Japanese Patients with Acute Schizophrenia: A 1-Year Observational Study under Routine Clinical Practice in Japan. Open Journal of Psychiatry, 5, 301-309. doi: 10.4236/ojpsych.2015.53034.

[1]   Haro, J.M., Novick, D., Belger, M. and Jones, P.B. (2006) Antipsychotic Type and Correlates of Antipsychotic Treatment Discontinuation in the Outpatient Treatment of Schizophrenia. European Psychiatry, 21, 41-47.

[2]   Bitter, I., Treuer, T., Dyachkova, Y., Martenyi, F., McBride, M. and Ungvari, G.S. (2008) Antipsychotic Prescription Patterns in Outpatient Settings: 24-Month Results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Study. European Neuropsychopharmacology, 18, 170-180.

[3]   Karagianis, J., Novick, D., Pecenak, J., Haro, J.M., Dossenbach, M., Treuer, T., Montgomery, W., Walton, R. and Lowry, A.J. (2009) Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): Baseline Characteristics of Pan-Regional Observational Data from More than 17,000 Patients. International Journal of Clinical Practice, 63, 1578-1588.

[4]   Kuramochi, M., Ono, H., Fujikoshi, S., Tokimoto, T., Nishiuma, S. and Takahashi, M. (2009) Safety and Efficacy of Olanzapine in Patients with Schizophrenia in Acute Phase: Analysis Based on the Starting Dose of Olanzapine. Japanese Journal of Clinical Psychopharmacology, 12, 1179-1197.

[5]   Ye, W., Nakahara, N., Takahashi, M. and Ascher-Svanum, H. (2011) Characteristics of Outpatients Initiated on Olanzapine versus Risperidone in the Treatment of Schizophrenia in Japan: A Healthcare Database Analysis. The Japanese Society of Clinical Neuropsychopharmacology, 2, 1-8.

[6]   Takahashi, M., Fujikoshi, S., Nakahara, N. and Iyo, M. (2013) The Continuation Rate of Monotherapy with Olanzapine or Other Antipsychotic Drugs in Patients with Acute-Phase Schizophrenia—A 1-Year Observational Study in Routine Clinical Practice. Japanese Journal of Clinical Psychopharmacology, 16, 1649-1660.

[7]   Hatta, K., Sato, K., Hamakawa, H., Takebayashi, H., Kimura, N., Ochi, S., Sudo, Y., Asukai, N., Nakamura, H., Usui, C., Kawabata, T., Hirata, T. and Sawa, Y. (2009) Effectiveness of Second-Generation Antipsychotics with Acute-Phase Schizophrenia. Schizophrenia Research, 113, 49-55.

[8]   Nishiuma, S., Takagaki, N., Sakaridani, M., Fujikoshi, S., Takahashi, M. and Yagi, G. (2008) Final Report of the Post-marketing Prospective Study in Patients with Schizophrenia Using Olanzapine. Japanese Journal of Clinical Psychopharmacology, 11, 1107-1124.

[9]   Seroquel® Package Insert. (2015) Astellas Pharma, Inc. Tokyo, Japan.

[10]   Zyprexa® Package Insert. (2015) Eli Lilly Japan K.K. Kobe, Japan.